Competitive grant funding represented more than 58 per cent ($36 million) of IMB’s total income in 2013 ($62 million), reflecting the high quality and scientific importance of our research.


The institute performed well in the major competitive grant rounds offered during the year by the Australian Research Council (ARC), National Health and Medical Research Council (NHMRC), and the Queensland Government. IMB achieved above national average success rates, recording a 47.4 per cent success rate against a national average success rate of 21.4 per cent for ARC Discovery Project grants, and a 45 per cent success rate against a national average success rate of 20.5 per cent for NHMRC Project grants.

During 2013, IMB received funding to lead a number of international research projects with some of the world’s top scientists in their respective fields. Notably, work began on the institute’s first NHMRC-European Union Collaborative Research Grant. Led by Professor Melissa Little, the collaborative project involves a multinational research team investigating cellular therapies for kidney disease. Professor Matt Cooper also received funding to lead an Australia-India Strategic Research Fund project to identify cellular immunotherapy targets and develop acid-stable analogues suitable for future development as new treatments for type 2 diabetes and other inflammatory disorders.

In 2013, funding commenced for the following grants:

 

 

  • 5 ARC Linkage grants totalling $2,361,845
  • 9 ARC Discovery Project grants totalling $4,035,000
 
  • 1 NHMRC Development grant totalling $513,630
  • 1 NHMRC EU FP7 Collaboration grant totalling $754,448
  • 1 NHMRC Program grant totalling $7,228,415
  • 17 NHMRC Project grants totalling $9,714,037
 
  •  1 Australia-India Strategic Research Fund project grant totalling $282,365

 

 

 

 


 

 

 

 

 

 

 

On this site

Go to top